Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KCNA4 | P22459 | 1/20 | 0.46 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.46 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biphenyl SCHEMBL28725381 | 0.93 | MEN1 (0.56) | CYP2C19MEN1KMT2ATSHRKCNA4 | |
| SCHEMBL2045490 | 0.90 | MEN1 (0.58) | CYP2C19MEN1KMT2ATSHRKCNA4 | |
| SCHEMBL733501 | 0.90 | CYP2C19 (0.58) | CYP2C19MEN1KMT2ATSHRKCNA4 | |
| SCHEMBL11515285 | 0.87 | MEN1 (0.56) | CYP2C19MEN1KMT2ATSHRKCNA4 | |
| SCHEMBL11512989 | 0.87 | MEN1 (0.56) | CYP2C19MEN1KMT2ATSHRKCNA4 | |
| SCHEMBL3597677 | 0.85 | MEN1 (0.48) | CYP2C19MEN1KMT2ATSHR | |
| SCHEMBL9451016 | 0.85 | MEN1 (0.44) | CYP2C19MEN1KMT2ATSHRKCNA4 | |
| SCHEMBL5946282 | 0.83 | CYP2C19 (0.62) | CYP2C19MEN1KMT2ATSHRKCNA4 | |
| SCHEMBL16884712 | 0.80 | MEN1 (0.44) | CYP2C19MEN1KMT2ATSHRKCNA4 | |
| SCHEMBL1106845 | 0.80 | CHRM2 (0.44) | CYP2C19MEN1KMT2ATSHRKCNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024032715-A1 | HYDRAZIDE COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳微芯生物科技股份有限公司 | 2024-02-15 | — | — | WO | claimed |
| CN-116730995-A | Hydrazide compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-09-12 | — | — | CN | claimed |
| CN-116410374-A | Star-branched telechelic polyisobutene, and preparation method and application thereof | 北京石油化工学院 | 2023-07-11 | — | — | CN | claimed |
| WO-2023064195-A1 | CGRP ANTAGONISTS FOR TREATING TRIGEMINAL NEURALGIA | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-04-20 | — | — | WO | claimed |
| WO-2023034467-A2 | CGRP ANTAGONISTS FOR TREATING SKIN CONDITIONS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | claimed |
| WO-2023034466-A1 | CGRP ANTAGONISTS FOR TREATING PSORIASIS | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-03-09 | — | — | WO | claimed |
| US-10669250-B2 | Hypervalent iodine CF2CF2X reagents and their use | ETH ZURICH (CH) | 2020-06-02 | — | — | US | claimed |
| CN-110343109-A | A kind of dihydro pteridinone-sulfonic acid amide derivatives and its pharmaceutically acceptable salt, preparation method and its application | 郑州大学 | 2019-10-18 | — | — | CN | claimed |
| US-20190040036-A1 | HYPERVALENT IODINE CF2CF2X REAGENTS AND THEIR USE | ETH ZURICH (CH) | 2019-02-07 | — | — | US | claimed |
| CN-108129462-A | A kind of dioxolanyl benzimidazole compound and preparation method thereof | 广东工业大学 | 2018-06-08 | — | — | CN | claimed |
| EP-0428849-A2 | Retroviral protease inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-05-29 | — | — | EP | claimed |
| EP-0400779-A1 | Biological production of novel cyclohexadienediols | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1990-12-05 | — | — | EP | claimed |
| EP-0370454-A2 | Renin-inhibiting amino diol derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | claimed |
| EP-0177913-B1 | CYCLOHEXENONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES | BASF Aktiengesellschaft (DE) | 1990-01-03 | — | — | EP | claimed |
| US-4624696-A | Cyclohexenone derivatives and their use for controlling undesirable plant growth | BASF AKTIENGESELLSCHAFT (DE) | 1986-11-25 | — | — | US | claimed |
| EP-0177913-A1 | Cyclohexenone derivatives, process for their preparation and their use as herbicides | BASF Aktiengesellschaft (DE) | 1986-04-16 | — | — | EP | claimed |
| EP-0014928-B1 | PIPERIDINOPROPYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS | Roche Diagnostics GmbH (DE) | 1982-05-05 | — | — | EP | claimed |
| US-4304921-A | Method of preparing β-halo esters from cyclic acetals | VANDERBILT UNIVERSITY (US) | 1981-12-08 | — | — | US | claimed |
| US-4192720-A | Electrodeposition process for forming amorphous silicon | EXXON RESEARCH & ENGINEERING CO. (US) | 1980-03-11 | — | — | US | claimed |
| US-4180646-A | BIOERODABLE SUSTAINED RELEASE COTAINGS | ALZA CORPORATION (US) | 1979-12-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10669250-B2 | Hypervalent iodine CF2CF2X reagents and their use | TPO, FANCF, FANCI | CYP2C19 2850/4885MEN1 220/4885KMT2A 741/4885 |
| US-20190040036-A1 | HYPERVALENT IODINE CF2CF2X REAGENTS AND THEIR USE | TPO, FANCF, FANCI | CYP2C19 2850/4885MEN1 220/4885KMT2A 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.